Friboulet, Luc
Inserm · Université Paris-Saclay
3 papers on CoChatORCID 0000-0002-1129-4978
Most cited papers
- Verified
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 708
- Verified
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., et al. (2018) · Cancer Discovery
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 322
- Verified
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 321
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free